Search results
Showing 226 to 240 of 1242 results for public health guidance
People can comment on our guidance at specific stages in its development.
In development Reference number: GID-TA11519 Expected publication date: 30 September 2026
We are listening to your views on this Technology appraisal guidance. Comments close 29 June 2026.
Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628
In development Reference number: GID-TA11826 Expected publication date: TBC
Awaiting development Reference number: GID-TA11813 Expected publication date: TBC
This guideline covers safe and effective use of medicines in health and social care for people taking 1 or more medicines. It aims to ensure that medicines provide the greatest possible benefit to people by encouraging medicines reconciliation, medication review, and the use of patient decision aids.
Alcohol use: risk assessment for people with depression or anxiety (IND198)
This indicator covers the percentage of patients with a new diagnosis of depression or anxiety in the preceding 12 months who have been screened for hazardous drinking using the FAST or AUDIT-C tool in the 3 months before or after their diagnosis being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM177
sitting on our executive team. About us Our board Executive team Guidance executive Policies, procedures and reports Corporate...
This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes
Involving you in the development of NICE guidance.
Involving you in the development of NICE guidance.
This guideline covers support for disabled children and young people with severe complex needs, from birth to 25 years. It aims to encourage education, health and social care services to work together and provide more coordinated support to children and young people, and their families and carers.
Show all sections
Sections for NG213
- Overview
- Recommendations on support for all disabled children and young people with severe complex needs
- Recommendations on specialist support for disabled children and young people with particular needs
- Recommendations on service organisation, integration and commissioning
- Terms used in this guideline
- Recommendations for research
- Rationale and impact for recommendations on supporting all disabled children and young people with severe complex needs
- Rationale and impact for recommendations on specialist support for disabled children and young people with particular needs
This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.
In development Reference number: GID-HST10067 Expected publication date: 19 August 2026
This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.
View quality statements for QS65Show all sections
Sections for QS65
- Quality statements
- Quality statement 1: Testing and vaccination for hepatitis B
- Quality statement 2: Referral for specialist care
- Quality statement 3: Referral to and assessment by specialist care for pregnant women who are identified as hepatitis B surface antigen-positive at antenatal screening
- Quality statement 4: Complete course of neonatal hepatitis B vaccination and blood testing at 12 months
- Quality statement 5: Personalised care plan
- Quality statement 6: Monitoring people with chronic hepatitis B infection who do not meet the criteria for antiviral treatment
- Quality statement 7: 6-monthly surveillance testing for hepatocellular carcinoma in adults with chronic hepatitis B infection who have significant liver fibrosis or cirrhosis